Bright Peak Therapeutics
San Diego, US · Founded 2019 · Delaware corporation · 33 employees on LinkedIn · 9 known investors
Find your way into Bright Peak Therapeutics
208 people in our graph share verified history with the Bright Peak Therapeutics team — schools, employers, funds. One of them is your warm intro.
Pavan Ongoleunlockedknows Vijaya Pattabiraman · together at Anna University Chennai (overlapped)
×10knows the team · via ETH Zurich
knows the team · via Dr. Reddy's Laboratories
Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform. The company operates in the immuno-oncology drug development space.
Founders & leadership
Bright Peak Therapeutics was founded in 2019 by Vijaya Pattabiraman and Jeffrey Bode.
VP
Vijaya PattabiramaninCo-founder & Chief Technology OfficerVijaya Pattabiraman is co-founder and CTO of Bright Peak Therapeutics, where he leads discovery and preclinical development programs in immuno-oncology. He has built expertise in protein and small molecule engineering for therapeutic applications through prior academic and translational research.
JB
Jeffrey BodeinScientific co-founder; Professor at ETH Zürich
FW
Fredrik WiklundChief Executive Officer
CS
Christine SiuNamed on SEC filing
MR
BK
Bertolt KreftNamed on SEC filing
Board
TW
AM
JR
Investors · 9
RA Capital✓ verifiedBoston
Johnson & Johnson Innovation – JJDC✓ verifiedNew Brunswick
Versant Ventures✓ verifiedSan Francisco · $250K – $5Mvia Alex Mayweg · board
VenrockPalo Alto · $500K – $10M
AlexandriareportedPasadena
BlackRockreportedWilmington
Fidelity Investmentsreported · 2 sourcesBoston
Invusreported · 2 sourcesNew York
Qatar Investment Authorityreported · 2 sourcesDoha
Funding
SEC filings, press & company announcements$196.5M disclosed across 2 of 4 rounds · 2021–2026
- Undisclosed amountSeries CAug 2026Source ↗
▶$90MraisedJun 2024 · 21 investors · OtherRule 506(b)
▶$90MraisedJun 2024 · 21 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Bertolt KreftExecutive Officer
- Laura ShawverDirector
- Tom WoiwodeDirector
- Vijaya PattabiramanExecutive Officer
- Matthew RobbinsExecutive Officer
- Leena GandhiDirector
- Asish XavierDirector
- Christine SiuDirector
- Fredrik WiklundExecutive Officer, Director
- Emily MinkowDirector
- Jon WiggintonExecutive Officer
- Jacob ChackoDirector
- Offering amount
- $90M
- Amount sold
- $90M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$106.5MraisedJun 2021 · 17 investors · OtherRule 506(b)
▶$106.5MraisedJun 2021 · 17 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Fredrik WiklundExecutive Officer, Director
- Christine SiuDirector
- Michael RosenzweigDirector
- Bertolt KreftExecutive Officer
- Tom WoiwodeDirector
- Alexander MaywegDirector
- Josh ResnickDirector
- Offering amount
- $106.5M
- Amount sold
- $106.5M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapBioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
bright-minds4 shared keywordsBright Minds Biosciences develops selective serotonin receptor agonists (5-HT2A and 5-HT2C) without 5-HT2B activity, built on a proprietary chemistry platform. The company targets central nervous system and brain disorders through serotonin regulation.
ブライトパス・バイオ㈱4 shared keywordsBrightPath Bio develops novel cancer immunotherapy medicines and cell therapy treatments that enhance the body's natural immune response to eliminate cancer cells. The company builds a platform for developing cell and antibody therapeutics across different cancer types and target antigens, with plans to expand into other immune-modulation therapeutic areas.
Companies competing with Bright Peak Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-IL18 Immunoconjugate Program Into Clinical Trials, Business Wires News - AsiaOneasiaone.com · Aug 2026Frequently asked questions
- What does Bright Peak Therapeutics do?
- Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform. The company operates in the immuno-oncology drug development space.
- Who founded Bright Peak Therapeutics?
- Bright Peak Therapeutics was founded by Vijaya Pattabiraman, Jeffrey Bode in 2019.
- Who are Bright Peak Therapeutics's investors?
- Bright Peak Therapeutics's investors include RA Capital, Johnson & Johnson Innovation – JJDC, Versant Ventures, Venrock, Alexandria, BlackRock, Fidelity Investments, Invus and 1 more.
- How much funding has Bright Peak Therapeutics raised?
- Bright Peak Therapeutics has disclosed $196.5M raised across 2 of its 4 known rounds.
- Where is Bright Peak Therapeutics headquartered?
- Bright Peak Therapeutics is headquartered in San Diego, US.